The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?

David J Benjamin; Arash Rezazadeh Kalebasty; Vinay Prasad

doi:10.1016/j.euo.2024.02.010

The Overall Survival Benefit in EV-302: Is Enfortumab Vedotin plus Pembrolizumab the New Frontline Standard of Care for Metastatic Urothelial Carcinoma?

Eur Urol Oncol. 2024 Mar 13:S2588-9311(24)00058-0. doi: 10.1016/j.euo.2024.02.010. Online ahead of print.

Authors

David J Benjamin¹, Arash Rezazadeh Kalebasty², Vinay Prasad³

Affiliations

¹ Hoag Family Cancer Institute, Newport Beach, CA, USA. Electronic address: david.benjamin@hoag.org.
² Division of Hematology and Oncology, Department of Medicine, University of California-Irvine, Orange, CA, USA.
³ Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, CA, USA.

PMID: 38485615
DOI: 10.1016/j.euo.2024.02.010

Abstract

Recent findings reported for the phase 3 EV-302 trial indicate a survival benefit from enfortumab vedotin plus pembrolizumab versus chemotherapy in metastatic urothelial carcinoma. We discuss several key points regarding post-protocol therapies, extending the duration of therapy, toxicity, and costs, all of which may have a bearing on how physicians and patients balance the benefit against the potential harms associated with this regimen.

Publication types

Editorial